We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Teamsters Union, et al v. Warner Chilcott Limited, et al

  1. November 21, 2018

    Consumer Groups Push 1st Circ. To Redo Asacol Class Cert.

    Law professors and two consumer interest groups urged the First Circuit on Tuesday to reconsider a decision last month decertifying a class of buyers who allegedly overpaid for the ulcerative colitis drug Asacol, arguing that class actions can't be disqualified just because some class members never suffered an injury.

  2. October 16, 2018

    1st Circ. Overturns Class Cert. In Allergan Price Fight

    The First Circuit has overturned certification of a class of buyers who purportedly bought Allergan medicines at artificially high prices, saying the suit didn't offer a way to weed out large numbers of purchasers who never suffered any injury.

  3. March 6, 2018

    Legal Group Urges 1st Circ. To Flip Asacol Class Cert.

    The Washington Legal Foundation on Monday backed Allergan PLC in a fight over class certification, telling the First Circuit that a Massachusetts federal judge shouldn’t have certified a class of insurers who paid for an ulcerative colitis drug without parties tied to each state involved in the product-hopping suit.

  4. February 26, 2018

    Allergan Urges 1st Circ. To Reverse Asacol Class Cert.

    Allergan PLC urged the First Circuit on Friday to reverse the certification of a class of buyers of an anti-inflammatory drug, accusing the putative class of “bootstrapping” claims from purchasers of the drug in just four states to bring claims under dozens of other states’ antitrust laws.

  5. January 25, 2018

    Asacol Antitrust Trial Delayed To Let Allergan Appeal Class

    The First Circuit on Thursday granted an indefinite delay of an antitrust trial slated to start next week, allowing Allergan PLC to appeal the certification of a class of unions and grocers who claim the company and a subsidiary manipulated the market with a monopolistic hard switch of available anti-inflammatory drugs.